Add-on Acquisition • Life Science

Ensoma Acquires Twelve Bio

On January 5, 2023, Ensoma acquired life science company Twelve Bio

Acquisition Context

This is Ensoma’s 1st transaction in the Life Science sector.
This is Ensoma’s 1st transaction in Denmark.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	January 5, 2023
Target	Twelve Bio
Sector	Life Science
Buyer(s)	Ensoma
Deal Type	Add-on Acquisition

Target Company

Twelve Bio

Copenhagen, Denmark

Twelve Bio is a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas technology. The company has advanced foundational insights from X-ray crystallography and cryogenic electron microscopy to further engineer and evolve CRISPR-Cas12a into wholly novel sequences with unique properties useful for a range of DNA editing strategies. Twelve Bio was formed in 2019 and is based in Copenhagen, Denmark.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Ensoma

Boston, Massachusetts, United States

Category	Company
Sector	Life Science

DESCRIPTION

Ensoma is a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system. The company’s Engenious platform combines innovative delivery technology with the full DNA editing toolkit to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, Massachusetts.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
Country: Denmark	1 of 1
Year: 2023	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Denmark M&A - 2023 M&A